Humacyte announced today that Symvess has been awarded Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency.
ECAT is an internet system that provides the Department of Defense (DOD) and other federal agencies with access to manufacturers’ and distributors’ products. The approval makes Symvess available to healthcare professionals treating military service members, veterans, and other patients receiving care at DOD and U.S. Department of Veterans Affairs facilities.
Symvess (acellular tissue engineered vessel-tyod) was approved in the extremity vascular trauma indication by the Food and Drug Administration (FDA) in December 2024.
“We are pleased that Symvess is now listed in the ECAT system, making the product more readily available to healthcare professionals treating military personnel and their families,” said Laura Niklason, president and chief executive officer of Humacyte. “We have received positive feedback in our interactions with a number of DOD hospitals, and we look forward to making Symvess available to more patients in need.”
Humacyte advises that, for uses other than the FDA approval in the extremity vascular trauma indication, the acellular tissue engineered vessel (ATEV) is an investigational product and has not been approved for use or sale by the FDA or any other regulatory agency.
